Braidwell LP Argenx Se Transaction History

Braidwell LP

$1.63 Billion
Q2 2025

A detailed history of Braidwell LP transactions in Argenx Se stock. As of the latest transaction made, Braidwell LP holds 194,491 shares of ARGX stock, worth $155 Million. This represents 6.57% of its overall portfolio holdings.

Number of Shares

194,491

Previous 160,849 20.92%

Holding current value

$155 Million

Previous $95.2 Million 12.61%

% of portfolio

6.57%

Previous 5.84%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$532.27 - $656.65 $17.9 Million - $22.1 Million	33,642 Added 20.92%	194,491 $107 Million
Q1 2025 May 15, 2025	BUY	$571.0 - $671.75 $45.7 Million - $53.8 Million	80,083 Added 99.15%	160,849 $95.2 Million
Q4 2024 Feb 14, 2025	SELL	$520.52 - $638.33 $8.31 Million - $10.2 Million	-15,958 Reduced 16.5%	80,766 $49.7 Million
Q3 2024 Nov 14, 2024	SELL	$434.22 - $551.9 $30.5 Million - $38.7 Million	-70,200 Reduced 42.06%	96,724 $52.4 Billion
Q2 2024 Aug 14, 2024	SELL	$356.01 - $451.55 $18.8 Million - $23.9 Million	-52,900 Reduced 24.06%	166,924 $71.8 Billion
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $23.8 Million - $27.5 Million	66,620 Added 43.48%	219,824 $86.5 Billion
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $51.9 Million - $77.5 Million	153,204 New	153,204 $58.3 Billion
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $8.22 Million - $9.93 Million	-24,600 Reduced 50.0%	24,600 $9.17 Billion
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $16.8 Million - $19.8 Million	49,200 New	49,200 $18.6 Billion

Others Institutions Holding ARGX

# of Institutions

492

Shares Held

28.2M

Call Options Held

370K

Put Options Held

211K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $44.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.

Account